Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Parkinson's Disease and Behavioral Complications: Executive Summary
2.1 High Unmet Need Remains for Disease-Modifying Pharmacotherapies
2.2 Large and Innovative Parkinson's Disease Pipeline Indicates Shift Towards Disease-Modifying Approaches
2.3 Novel Gene Therapies Attract High Levels of Investment in Parkinson's Disease
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Sustained Innovation in Parkinson's Disease
4.4 Epidemiology for Parkinson's Disease
4.5 Overview for Marketed Products
4.6 Overview for Behavioral Complications in Parkinson's Disease
4.6.1 Overview of Parkinson's Disease-Associated Dementia
4.6.2 Overview of Parkinson's Disease-Associated Psychosis
5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between the Parkinson's Disease Market and Pipeline by Therapeutic Target Family
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Targets Within the Pipeline
6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Pipeline Programs Targeting Alpha Synuclein for Parkinson's Disease and Parkinson's Disease-Associated Dementia
6.3 Pipeline Programs Targeting Microtubule-Associated Protein Tau for Parkinson's Disease
6.4 Pipeline Programs Targeting Glial Cell Line-Derived Neurotrophic Factor for Parkinson's Disease
6.5 Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 and Metabotropic Glutamate Receptor 5 for Parkinson's Disease
6.6 Pipeline Programs Targeting GDNF Family Receptor Alpha 1 and GDNF Family Receptor Alpha 2 for Parkinson's Disease
6.7 Pipeline Programs Targeting Pituitary Adenylate Cyclase-Activating Polypeptide Type I Receptor for Parkinson's Disease
6.8 Pipeline Programs Targeting Caveolin-1 for Parkinson's Disease-Associated Dementia
6.9 Pipeline Programs Targeting Mitogen-Activated Protein Kinase 14 for Parkinson's Disease-Associated Dementia
7 Key Players and Deals
7.1 Overview
7.1.1 AbbVie and Voyager Therapeutics Enter into Co-development Agreement
7.1.2 Axovant Sciences Enters into Licensing Agreement with Oxford Biomedica
7.1.3 Pfizer Enters into Licensing Agreement with Arvinas
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 About the Authors
8.4.1 Analyst
8.4.2 Therapy Area Director
8.4.3 Global Director of Therapy Analysis and Epidemiology
8.4.4 Global Head and EVP of Healthcare Operations and Strategy
8.5 About GlobalData
8.6 Contact Us
8.7 Disclaimer

1.1 List of Tables
Table 1: Parkinson's Disease and Behavioral Complications, Global, Modified Hoehn and Yahr Scale of Parkinson's Disease Symptoms, 2017
Table 2: Parkinson's Disease and Behavioral Complications, Global, Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), 2008
Table 3: Parkinson's Disease and Behavioral Complications, Diagnosed Parkinson's Disease Prevalent Cases (N) (Millions), 2016-2026

1.2 List of Figures
Figure 1: Parkinson's Disease and Behavioral Complications, Global, Indirect and Direct Pathways in Basal Ganglia, 2019
Figure 2: Parkinson's Disease and Behavioral Complications, Global, Parkinson's Disease Market by Molecular Target, 2019
Figure 3: Parkinson's Disease and Behavioral Complications, Global, Parkinson's Disease Pipeline by Stage of Development and Molecule Type, 2019
Figure 4: Parkinson's Disease and Behavioral Complications, Global, Pipeline for Parkinson's Disease-Associated Dementia and Parkinson's Disease-Associated Psychosis by Stage of Development, 2019
Figure 5: Parkinson's Disease and Behavioral Complications, Global, Pipeline for Parkinson's Disease-Associated Dementia by Molecule Type, 2019
Figure 6: Parkinson's Disease and Behavioral Complications, Global, Parkinson's Disease Pipeline by Molecular Target and Stage of Development, 2019
Figure 7: Parkinson's Disease and Behavioral Complications, Global, Pipeline for Parkinson's Disease-Associated Dementia and Parkinson's Disease-Associated Psychosis by Molecular Target, 2019
Figure 8: Parkinson's Disease and Behavioral Complications, Global, Distribution of Pipeline and Marketed Parkinson's Disease Products by Molecular Target Class, 2019
Figure 9: Parkinson's Disease and Behavioral Complications, Global, Distribution of Parkinson's Disease Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
Figure 10: Parkinson's Disease and Behavioral Complications, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Parkinson's Disease Products by Stage of Development and Molecular Target Class, 2019
Figure 11: Parkinson's Disease and Behavioral Complications, Global, Ratio of First-in-Class Products to First-in-Class Targets in the Parkinson's Disease Pipeline by Stage of Development and Molecular Target Class, 2019